On Friday, Haemonetics Corporation (NYSE: HAE) spotted trading -15.71% off 52-week high price. On the other end, the stock has been noted 47.45% away from the low price over the last 52-weeks. The stock changed -1.21% to recent value of $118.31. The stock transacted 214411 shares during most recent day however it has an average volume of 331.97K shares. The company has 50.82M of outstanding shares and 50.24M shares were floated in the market.
Haemonetics Corporation (HAE) reported global commercial availability for the four-channel TEG® 6s PlateletMapping® ADP & AA assay cartridge. Intended for use with the TEG 6s Hemostasis Analyzer System, the cartridge is FDA cleared in the U.S. for use in cardiology and cardiovascular surgery and is CE-marked and accessible internationally with broader indications.
“The release of the PlateletMapping ADP & AA cartridge marks another milestone in our commitment to developing meaningful technologies that help improve the efficiency and effectiveness of care in critical areas of medicine,” stated Stew Strong, President, Global Hospital at Haemonetics. “On the heels of our FDA clearance for use of the TEG 6s analyzer in U.S. adult trauma settings, this product release further strengthens our TEG portfolio, making it the only cartridge-based hemostasis analyzer that allows a clinician to assess both global hemostasis and platelet function at the site of care.”
“Platelet function can be affected by factors such as genetics, antiplatelet therapy or surgical procedures,” stated Jan Hartmann, M.D., Vice President, Medical Affairs at Haemonetics. “The PlateletMapping ADP & AA cartridge provides clinicians with the timely and relevant results they need to assess the patient’s platelet function, and ways that it might be impaired. This information can help them more confidently determine a diagnosis and appropriate therapy.”
Its earnings per share (EPS) expected to touch remained -24.20% for this year while earning per share for the next 5-years is expected to reach at 12.00%. HAE has a gross margin of 49.30% and an operating margin of 9.00% while its profit margin remained 6.90% for the last 12 months. According to the most recent quarter its current ratio was 2.4 that represents company’s ability to meet its current financial obligations. The price moved ahead of -2.29% from the mean of 20 days, -4.45% from mean of 50 days SMA and performed 7.45% from mean of 200 days price. Company’s performance for the week was -1.79%, -1.56% for month and YTD performance remained 18.25%.